ALDX — Aldeyra Therapeutics Share News
0.000.00%
Last trade - 00:00Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug
US FDA declines to approve Aldeyra's eye disorder drug, shares slump (updated)
US FDA declines to approve Aldeyra's drug for eye disorder
Brief: Aldeyra Therapeutics Receives Complete Response Letter From The U.S. Food And Drug Administration For The Reproxalap New Drug Application For The Treatment Of Signs And Symptoms Of Dry Eye Disease
U.S. STOCKS ON THE MOVE-Sunrun, PayPal, Caris
U.S. STOCKS ON THE MOVE-ADP, Bunge, Sunrun
U.S. STOCKS ON THE MOVE-premarket
Aldeyra falls after FDA extends review of eye disease drug
Brief: Aldeyra Therapeutics Announces PDUFA Extension Of The New Drug Application Of Reproxalap For The Treatment Of Dry Eye Disease
Brief: Aldeyra Therapeutics Announces Expansion of RASP Platform
Brief: Aldeyra Therapeutics Announces Positive Results From Phase 2 Clinical Trial In Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline On Next-Generation Molecules
Brief: Aldeyra Therapeutics Receives Fast Track Designation For Adx‑2191 For The Treatment Of Retinitis Pigmentosa
Aldeyra Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview